SAKK Swiss Group for Clinical Cancer Research Overview | SignalHire Company Profile
BIG Members | Breast International Group
SAKK Swiss Group for Clinical Cancer Research | LinkedIn
Tweets with replies by SAKK (@SAKK_ch) / Twitter
Oesophageal cancer: exploring controversies overview of experts' opinions of Austria, Germany, France, Netherlands and Switzerland – topic of research paper in Clinical medicine. Download scholarly article PDF and read for free on
Utility of the 21-Gene Recurrence Score in Node-Positive Breast Cancer
Talidox | InnoMedica
ZOOM SAKK 30/10 HOVON 103 Indication ... - Cancer Lausanne
PDF) Docetaxel, Cisplatin, and Fluorouracil; Docetaxel and Cisplatin; and Epirubicin, Cisplatin, and Fluorouracil As Systemic Treatment for Advanced Gastric Carcinoma: A Randomized Phase II Trial of the Swiss Group for Clinical Cancer
Methods in Clinical Cancer Research (MCCR) 2021 | ESMO
Adding cetuximab to capecitabine plus oxaliplatin (XELOX) in first-line treatment of metastatic colorectal cancer: a randomized phase II trial of the Swiss Group for Clinical Cancer Research SAKK - ScienceDirect
Indication Lymphome agressif à cellules B récidivant ou ... - CHUV
Swiss Group for Clinical Cancer Research (SAKK) – Breast Cancer Project Group | Breast Cancer Online | Cambridge Core
GitHub - IDSC-io/sakk: Swiss Group for Clinical Cancer Research SAKK
SAKK/Pfizer Award
Home | SAKK
SAKK | BIG against breast cancer
Swiss Medical Weekly - Update Swiss guideline for counselling and testing for predisposition to breast, ovarian, pancreatic and prostate cancer
International Journal of Colorectal Disease | Volume 32, issue 1
SAKK Swiss Group for Clinical Cancer Research Overview | SignalHire Company Profile
Organization
PDF) Ghielmini M, Rufibach K, Salles G, Leoncini-Franscini L, Léger-Falandry C, Cogliatti S, Fey M, Martinelli G, Stahel R, Lohri A, Ketterer N, Wernli M, Cerny T, Schmitz SFSingle agent rituximab in
Patient-reported outcomes of patients with advanced biliary tract cancers receiving gemcitabine plus capecitabine: a multicenter, phase II trial of the Swiss Group for Clinical Cancer Research. | Semantic Scholar
Home | SAKK
CAREFOR, The Clinical Academic Cancer Research Forum
Long‐term outcome of dasatinib first‐line treatment in gastrointestinal stromal tumor: A multicenter, 2‐stage phase 2 trial (Swiss Group for Clinical Cancer Research 56/07) - Montemurro - 2018 - Cancer - Wiley Online Library
